Intensity Therapeutics (INTS) Stock Overview
A late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INTS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Intensity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$3.17 |
| 52 Week Low | US$0.19 |
| Beta | 4.24 |
| 1 Month Change | -7.81% |
| 3 Month Change | 51.67% |
| 1 Year Change | -79.77% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.82% |
Recent News & Updates
Shareholder Returns
| INTS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | -0.7% | -0.2% |
| 1Y | -79.8% | 26.8% | 17.1% |
Return vs Industry: INTS underperformed the US Biotechs industry which returned 28% over the past year.
Return vs Market: INTS underperformed the US Market which returned 17% over the past year.
Price Volatility
| INTS volatility | |
|---|---|
| INTS Average Weekly Movement | 114.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INTS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INTS's weekly volatility has increased from 59% to 115% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Lew Bender | www.intensitytherapeutics.com |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. Fundamentals Summary
| INTS fundamental statistics | |
|---|---|
| Market cap | US$23.59m |
| Earnings (TTM) | -US$11.74m |
| Revenue (TTM) | n/a |
Is INTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.74m |
| Earnings | -US$11.74m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/29 17:57 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intensity Therapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Robert Wasserman | Benchmark Company |
| Kumaraguru Raja | Brookline Capital Markets |